Navigation Links
Histogen’s Composition for Hair Growth Receives US Patent
Date:9/17/2013

San Diego, CA (PRWEB) September 17, 2013

Histogen, Inc., a regenerative medicine company developing innovative therapies based on the products of cells grown under simulated embryonic conditions, today announced that the United States Patent & Trademark Office has issued patent 8,535,913, entitled “Soluble Composition for Promoting Hair Growth Produced by Hypoxic Culture of Fibroblast Cells”.

The patent, which is the fourth US patent issued to the Company, covers the liquid composition of proteins and cofactors that is secreted by multipotent stem cells through Histogen’s technology process, and the method of administering that composition to stimulate hair growth. Histogen’s Hair Stimulating Complex (HSC), covered by this new patent, is in clinical development as an injectable treatment for male pattern and female diffuse hair loss.

“We are extremely pleased that HSC, and future hair restoration treatments using this technology, are now bolstered by a US patent,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “At a time when the industry continues to uncover information about how cell-signaling results in hair growth and maintenance, patent protection for our unique composition of proteins and growth factors is of great benefit to Histogen and its future partners.”

Several factors critical to hair growth such as follistatin, VEGF and KGF, are present in HSC, and their secretion by the cells is stimulated by low oxygen and special culture conditions utilized by Histogen. The conditions under which the cells are manufactured not only upregulates genes associated with hair growth, but induces significantly increased production of these critical factors than seen with traditional culture conditions.

In two Company-sponsored clinical trials, HSC has resulted in statistically significant increases across hair growth parameters, including hair count, density and thickness. In addition, the treatment has shown efficacy in difficult-to-treat patient groups, including women, older subjects and those with temporal recession region hair loss. Histogen looks forward to progressing HSC to the next clinical stage, and to further analyzing its newly-patented composition.

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit http://www.histogen.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11129502.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Histogen’s Method of Generating Multipotent Stem Cells Receives US Patent
2. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
3. Bio/Pharmaceutical Contract Manufacturing - Industry Analysis of Dose Manufacturing by the Numbers: Composition, Size, Market Shares, Profitability and Outlook
4. Downsizing and the Need for Increased Selling Effectiveness Fuel Delta Points Growth
5. RSB Spine, LLC Announces 2011 Revenue Growth
6. ERT Launches New Website to Support Significant Commercial Growth
7. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
8. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
9. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
10. Carbon nanotubes can double growth of cell cultures important in industry
11. CannaBANK Acquires Rights to License PharmaSpheres Patented Growth System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... JUPITER, Fla. (PRWEB) , ... June 10, 2019 ... ... breakthroughs in science and technology in an upcoming episode, scheduled to broadcast 4Q/2019. ... of the Eppendorf Group) and will educate viewers about how its technology facilitates ...
(Date:6/6/2019)... ... June 05, 2019 , ... WCCT Global, Inc ., a ... announced today that they will be receiving 3 awards at the 2019 CRO Leadership ... 2 awards in the categories of overall Quality and Compatibility (Access to desired markets, ...
(Date:5/31/2019)... ... 30, 2019 , ... A study released today in STEM ... the sustained release of human placental stem cell (HPSC)-derived conditioned medium (CM) to ... CM into the injured kidney, where it helped restore function and regenerate injured ...
(Date:5/14/2019)... ... May 13, 2019 , ... ... leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ ... The redesigned website aims to improve LDA’s ability to communicate directly with the ...
Breaking Biology Technology:
(Date:6/14/2019)... (PRWEB) , ... June 14, 2019 , ... Molecular diagnostics ... estimated to be $8,760 million in 2019. Major segments that are expected to ... are all broken out and forecasted as segments in Kalorama’s The World Molecular ...
(Date:6/11/2019)... ... 12, 2019 , ... With a rapidly growing customer base ... Geneious Biologics platform as a premium hub for bioinformatics and computer programming capabilities. ... Geneious team has done an excellent job accommodating our specific data, resulting in ...
(Date:6/6/2019)... CITY (PRWEB) , ... June 05, 2019 , ... ... packaging, announces the opening of a new network station and service center in ... — and 12th in the world — with more than $1.75 billion in ...
Breaking Biology News(10 mins):